ClinicalTrials.gg
CompletedNCT03723655Updated Feb 20, 2026

A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCM

A Phase 2/3 interventional study of mavacamten in Hypertrophic Cardiomyopathy, Obstructive Hypertrophic Cardiomyopathy and Non-obstructive Hypertrophic Cardiomyopathy, sponsored by Bristol-Myers Squibb. Completed at 68 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-20.

Sponsored by Bristol-Myers Squibb · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
314
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic — 3 open to participants now, 7 under way, 1 of them phase 3. MYK-461 · Cardiomyopathy, Hypertrophic.

Enrollment
2nd of 21
314 · median 75
Started
2018
with 3 others
Phase 2/3
Only one
of the 21
Registered
7th of 21
by date
Lead sponsor
10 of 21
Bristol-Myers Squibb

Among the 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic, this one is the 2nd largest by enrollment, is one of 4 that started in 2018, is the only one in phase 2/3, and was the 7th registered.

Cardiomyopathy, Hypertrophic

363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.

Browse Cardiomyopathy, Hypertrophic studies →

Open to participants now

3 of the 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About MYK-461

MYK-461: first FDA approval 2022 (CAMZYOS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing MYK-461 in Cardiomyopathy, Hypertrophic, or all of them as a file.
02

Study summary

Approximately 30 sites that enrolled participants in the MAVERICK-HCM (MYK-461-006) study in the United States (US) will initiate this study.

Approximately 90 sites that enrolled participants in the EXPLORER-HCM (MYK-461-005) study in the US, Europe, and Israel will initiate this study.

Note: Approximately 30 centers overlap between MAVERICK and EXPLORER.

03

Conditions studied

  • Hypertrophic Cardiomyopathy
  • Obstructive Hypertrophic Cardiomyopathy
  • Non-obstructive Hypertrophic Cardiomyopathy

Keywords

  • Symptomatic, left ventricular outflow tract gradient
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Has completed the Parent Study through to the EOS Visit within 90 days of consent. (Participants who are beyond the 90-day window from EOS Visit may be included in this study pending MyoKardia Medical Monitoring approval) Participants who prematurely discontinued from the Parent Study or the MAVA-LTE study may be considered for inclusion.
  • Has a body weight greater than 45 kg at the Screening Visit
  • Has adequate acoustic windows to enable accurate TTEs.
  • Has documented ≥ 50% by echocardiography core laboratory read of screening TTE at rest.
  • Has safety laboratory parameters (chemistry, hematology, coagulation, and urinalysis) within normal limits (according to the central laboratory reference range).
  • Female participants must not be pregnant or lactating and, if sexually active, must use one of the following highly effective methods from the Screening Visit through 90 days after the last dose of medicinal product (IMP).

In addition to the above contraceptive requirements for female participants, male partners must also use a contraceptive (eg. barrier, condom, or vasectomy).

Key Exclusion Criteria:

  • Has any abnormality considered by the investigator to pose a risk to participant safety (eg. second degree atrioventricular block type II).
  • Has a history of syncope or a history of sustained ventricular tachyarrhythmia with exercise between Parent Study EOS Visit and Screening Visit.
  • Has a history of resuscitated sudden cardiac arrest or known history of appropriate implantable cardioverter-defibrillator (ICD) discharge for life-threatening ventricular arrhythmia between Parent Study EOS Visit and Screening Visit. (Note: history of anti-tachycardia pacing (ATP) is allowed).• Currently treated with disopyramide or ranolazine (within 14 days prior to Screening) or treatment with disopyramide or ranolazine is planned during the study.
  • Has any acute or serious comorbid condition (eg. major infection or hematologic, renal, metabolic, gastrointestinal, or endocrine dysfunction) that, in the judgment of the Investigator, could lead to premature termination of study participation or interfere with the measurement or interpretation of the efficacy and safety assessments in the study.
  • History of malignant disease that developed since enrollment in the Parent Study.
  • Is unable to comply with the study requirements, including the number of required visits to the clinical site.
  • Has participated in a clinical trial in which the participant received any investigational drug (or is currently using an investigational device) within 30 days prior to Screening, or at least 5 times the respective elimination half-life (whichever is longer), except for participation in MAVERICK-HCM or EXPLORER-HCM. Prior participation in a non-interventional observational study is allowed.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
314 participants (actual)

Study arms

  • Experimental
    Group 1

    Active Treatment for participants with base target trough concentration

    Drug: mavacamten

  • Experimental
    Group 2

    Active Treatment for participants with higher target trough concentration

    Drug: mavacamten

  • Experimental
    Group 3

    Active Treatment for participants dose titrated to clinical response

    Drug: mavacamten

Interventions

  • mavacamten capsules

    Also known as: MYK-461

06

What researchers measure

Primary outcomes

  1. Frequency and severity of treatment-emergent adverse events and serious adverse events

    Time frame: 252 weeks

07

Study locations

68 sites
  • Local Institution - 0045
    Scottsdale, Arizona 85259, United States
  • Local Institution - 0058
    Los Angeles, California 90027, United States
  • Local Institution - 0066
    San Francisco, California 94143, United States
  • Local Institution - 0063
    Stanford, California 94305, United States
  • Local Institution - 0043
    New Haven, Connecticut 06520-8017, United States
  • Local Institution - 0067
    Jacksonville, Florida 32224, United States
  • Local Institution - 0050
    Chicago, Illinois 60611, United States
  • Local Institution - 0070
    Indianapolis, Indiana 46260, United States
  • Local Institution - 0049
    Iowa City, Iowa 52242, United States
  • Local Institution - 0054
    Boston, Massachusetts 02115, United States
  • Local Institution - 0051
    Ann Arbor, Michigan 48109, United States
  • Local Institution - 0074
    Grand Rapids, Michigan 49503, United States
  • Local Institution - 0048
    St Louis, Missouri 63110, United States
  • Local Institution - 0060
    New York, New York 10016, United States
  • Local Institution - 0056
    New York, New York 10032, United States
  • Local Institution - 0071
    Charlotte, North Carolina 28204, United States
  • Local Institution - 0047
    Durham, North Carolina 27710, United States
  • Local Institution - 0052
    Cincinnati, Ohio 45267, United States
  • Local Institution - 0044
    Portland, Oregon 97239, United States
  • Local Institution - 0068
    Bethlehem, Pennsylvania 18015, United States
  • Local Institution - 0046
    Philadelphia, Pennsylvania 19104, United States
  • Local Institution - 0064
    Pittsburgh, Pennsylvania 15213, United States
  • Local Institution - 0073
    Memphis, Tennessee 38104, United States
  • Local Institution - 0061
    Dallas, Texas 75390, United States
  • Local Institution - 0055
    Houston, Texas 77030, United States
  • Local Institution - 0057
    Houston, Texas 77030, United States
  • Local Institution - 0072
    Murray, Utah 84107-5701, United States
  • Local Institution - 0062
    Salt Lake City, Utah 84112, United States
  • Local Institution - 0053
    Charlottesville, Virginia 22903, United States
  • Local Institution - 0059
    Richmond, Virginia 23298, United States
  • Local Institution - 0065
    Seattle, Washington 98195, United States
  • Local Institution - 0002
    Aalst, 9300, Belgium
  • Local Institution - 0001
    Brussels, 1070, Belgium
  • Local Institution - 0003
    Edegem, 2650, Belgium
  • Local Institution - 0010
    Prague, 128 08, Czechia
  • Local Institution - 0009
    Prague, 140 21, Czechia
  • Local Institution - 0011
    Aarhus, 8000, Denmark
  • Local Institution - 0012
    Frederiksberg, 2000, Denmark
  • Local Institution - 0013
    Odense, 5000, Denmark
  • Local Institution - 0014
    Nantes, 44093, France
  • Local Institution - 0017
    Paris, 75013, France
  • Local Institution - 0016
    Paris, 75015, France
  • Local Institution - 0015
    Toulouse, 31059, France
  • Local Institution - 0020
    Bad Nauheim, 61231, Germany
  • Local Institution - 0018
    Dresden, 01277, Germany
  • Local Institution - 0019
    Göttingen, 37075, Germany
  • Local Institution - 0021
    Heidelberg, 69120, Germany
  • Local Institution - 0027
    Jerusalem, 9112001, Israel
  • Local Institution - 0024
    Petah Tikva, 4941492, Israel
  • Local Institution - 0022
    Ramat Gan, 52621, Israel
  • Local Institution - 0025
    Rehovot, 76100, Israel
  • Local Institution - 0023
    Safed, 13100, Israel
  • Local Institution - 0026
    Tel Aviv, 6423906, Israel
  • Local Institution - 0028
    Florence, 50139, Italy
  • Local Institution - 0029
    Maastricht, 6229 HX, Netherlands
  • Local Institution - 0030
    Rotterdam, 3015 CE, Netherlands
  • Local Institution - 0033
    Katowice, 40-555, Poland
  • Local Institution - 0034
    Krakow, 31-501, Poland
  • Local Institution - 0031
    Poznan, 61-848, Poland
  • Local Institution - 0032
    Warsaw, 04-628, Poland
  • Local Institution - 0036
    Almada, 2805-267, Portugal
  • Local Institution - 0035
    Lisbon, 1500-650, Portugal
  • Local Institution - 0038
    A Coruña, 15006, Spain
  • Local Institution - 0037
    El Palmar, 30120, Spain
  • Local Institution - 0040
    Madrid, 28034, Spain
  • Local Institution - 0039
    Majadahonda, 28222, Spain
  • Local Institution - 0041
    Seville, 41009, Spain
  • Local Institution - 0042
    London, W1G 8PH, United Kingdom
08

References and documents

Publications

  • Rader F, Oreziak A, Choudhury L, Saberi S, Fermin D, Wheeler MT, Abraham TP, Garcia-Pavia P, Zwas DR, Masri A, Owens A, Hegde SM, Seidler T, Fox S, Balaratnam G, Sehnert AJ, Olivotto I. Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results From the MAVA-LTE Study, EXPLORER-LTE Cohort. JACC Heart Fail. 2024 Jan;12(1):164-177. doi: 10.1016/j.jchf.2023.09.028. PubMed 38176782 ↗

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2018 to primary completion in Jan 2026, 87 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2018
First posted
Oct 29, 2018
StartActual
Sep 27, 2018
Primary completionActual
Jan 16, 2026
CompletionActual
Jan 16, 2026
Last update
Feb 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03723655
Responsible party
Sponsor
First posted
Oct 29, 2018
Start date
Sep 27, 2018
Primary completion
Jan 16, 2026
Completion
Jan 16, 2026
Last update
Feb 20, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MYK-461

Start the discussion